PDCD1 and nasopharyngeal carcinoma: At present, promising outcomes have been revealed by immunotherapy combined with radiotherapy in several types of malignancies, including NSCLC,[38] recurrent NPC,[39] etc. A clinical trial reported that toripalimab combined with intensity-modulated radiation therapy is tolerable and shows promising antitumor activity in patients with recurrent NPC.[39] Some studies on antibodies targeting PD-1 combined with radiotherapy in the treatment of LA-NPC are still in progress (NCT05097209, NCT03700476).